Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Non-Current Debt of $486.0 million for Q1 2026, up 56.27% year-over-year from $311.0 million in Q1 2025, and up 67.59% quarter-over-quarter from $290.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $486.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 56.27% year-over-year to $486.0 million; the TTM figure through Mar 2026 stood at $486.0 million (up 56.27% YoY), while the FY2025 annual figure was $290.0 million, down 7.94% from the prior year.
- Non-Current Debt for Q1 2026 stood at $486.0 million, up from $290.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $486.0 million in Q1 2026, with the low at $237.0 million in Q4 2022.
- The 5-year median for Non-Current Debt is $306.0 million (2025), against an average of $311.0 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt fell 7.94% in 2025, then soared 56.27% in 2026.
- Indivior Pharmaceuticals' Non-Current Debt stood at $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then surged by 32.91% to $315.0 million in 2024, then dropped by 7.94% to $290.0 million in 2025, then surged by 67.59% to $486.0 million in 2026.
- Business Quant data shows INDV's Non-Current Debt at $486.0 million in Q1 2026, $290.0 million in Q4 2025, and $304.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Indivior Pharmaceuticals | 4.56 Bn | 4.34 Bn | 294.00 Mn | 487.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 487.00 Mn |
| Mar 31, 2026 | 486.00 Mn |
| Dec 31, 2025 | 290.00 Mn |
| Sep 30, 2025 | 304.00 Mn |
| Jun 30, 2025 | 308.00 Mn |
| Mar 31, 2025 | 311.00 Mn |
| Dec 31, 2024 | 315.00 Mn |
| Dec 31, 2023 | 237.00 Mn |
| Dec 31, 2022 | 237.00 Mn |
| Dec 31, 2021 | 239.00 Mn |